The 2026 Compounded Semaglutide Ban, Explained

If you've been using compounded semaglutide to lose weight or manage diabetes, you've probably heard the bad news. The FDA has effectively banned compounding pharmacies from making their own versions of semaglutide — the active ingredient in Ozempic and Wegovy.

This affects millions of people. Compounded semaglutide was cheaper, easier to get, and for many patients, the only affordable option. Now it's going away.

Here's what happened, what it means for you, and what your options are going forward.

---

What Actually Happened

The story starts with a drug shortage. When Ozempic and Wegovy exploded in popularity in 2022 and 2023, Novo Nordisk (the company that makes them) couldn't keep up with demand. Pharmacies across the country ran out of stock. Patients with prescriptions couldn't fill them.

Under federal law, when an FDA-approved drug is in shortage, compounding pharmacies are allowed to make their own versions. So that's exactly what happened. Hundreds of compounding pharmacies began producing injectable semaglutide at a fraction of the brand-name price — sometimes as low as $150 to $300 per month compared to $1,000+ for Wegovy.

Telehealth companies like Hims & Hers built entire businesses around prescribing and shipping compounded semaglutide. It became a billion-dollar market almost overnight.

Then the shortage ended.

The Key Dates

Here's the timeline of how this unfolded:

• March–August 2022: FDA adds Wegovy and Ozempic to the drug shortage list. Compounding becomes legal.
• 2023–2024: Compounded semaglutide market booms. Telehealth platforms scale up. Estimated $1.5 billion in revenue for compounders in 2024 alone.
• October 2024: FDA declares the tirzepatide shortage (Mounjaro/Zepbound) resolved. Compounders given a wind-down period.
• December 19, 2024: FDA issues a declaratory order reaffirming the tirzepatide shortage is over. Sets enforcement deadlines.
• February 21, 2025: FDA officially removes semaglutide from the drug shortage list. Declares the shortage resolved.
• April 22, 2025: Deadline for 503A compounding pharmacies (state-licensed) to stop making semaglutide.
• May 22, 2025: Deadline for 503B outsourcing facilities to stop making semaglutide.
• Mid-2025 onward: FDA begins active enforcement — warning letters, seizures, and legal action against compounders still producing semaglutide.
• June 2025: Novo Nordisk publicly cuts ties with Hims & Hers over compounded semaglutide concerns.
• September 2025: FDA warns Hims & Hers to stop implying its compounded semaglutide is FDA-approved.
• Late 2025–2026: Compounders sue the FDA, calling the shortage declaration "reckless and arbitrary." Litigation ongoing.

---

Why the FDA Did This

The FDA's reasoning is straightforward: the shortage is over, so the legal basis for compounding is gone.

But there's more to it than that.

Safety Concerns Are Real

The FDA received more than 455 adverse event reports tied to compounded semaglutide and over 320 tied to compounded tirzepatide as of late February 2025. Some of these required hospitalization.

The main problems:

• Dosing errors: Compounded semaglutide often came in multi-dose vials that required patients to measure and inject their own doses. Some patients accidentally took too much. Some healthcare providers miscalculated doses.
• Quality control: Compounded drugs don't go through the same safety and effectiveness review as FDA-approved drugs. There's no guarantee that what's in the vial matches what's on the label.
• Counterfeits: The compounding boom opened the door to counterfeit and illegally marketed products, especially online. The FDA estimates that nearly half of online pharmacies offering GLP-1 medications may have been operating illegally.
• Semaglutide sodium: Some compounders used a salt form of semaglutide (semaglutide sodium) rather than the base form used in Ozempic and Wegovy. The FDA flagged this as a different substance that hasn't been proven safe or effective.

Novo Nordisk Pushed Hard

Let's be honest: the pharmaceutical industry wanted this. Novo Nordisk fought aggressively to end the shortage designation and shut down compounders who were eating into their market. Brand-name semaglutide products generate tens of billions in annual revenue. Every compounded vial represented lost sales.

That doesn't mean the safety concerns are fake. But it does mean the timeline was probably faster than it would have been without industry pressure.

---

What This Means If You're Currently Using Compounded Semaglutide

If you're one of the millions of people who switched to compounded semaglutide because you couldn't afford or access the brand-name versions, here's what you need to know:

Your Supply Will Run Out

Any legitimate compounding pharmacy has already stopped producing semaglutide or is in the final stages of winding down. If someone is still selling you "compounded semaglutide" in 2026, there's a good chance it's either:

1. Not actually semaglutide
2. Coming from an unlicensed or illegal source
3. Made overseas without quality controls

Be extremely careful. The risks of counterfeit products are serious — wrong doses, contamination, or completely different substances.

Don't Stop Cold Turkey (Talk to Your Doctor)

Semaglutide isn't a medication you should just stop taking without guidance. If you've been on it for weight loss, suddenly stopping can lead to:

• Rapid weight regain
• Blood sugar spikes (especially if you have diabetes)
• Increased appetite and cravings

Talk to your prescribing provider about a transition plan. If your provider was a telehealth platform that only offered compounded versions, you may need to find a new provider.

Your Telehealth Provider May Be Pivoting

Companies like Hims & Hers are transitioning away from compounded semaglutide. Some are partnering with manufacturers to offer brand-name medications. Others are shifting to different weight loss approaches. Check with your provider about what options they offer now.

---

Your Options Going Forward

The compounded semaglutide era is over, but you still have paths forward. Here are the main ones:

1. Brand-Name Wegovy or Ozempic (With Insurance)

If your insurance covers GLP-1 medications, this is the most straightforward option.

• Wegovy is FDA-approved specifically for weight loss in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related condition.
• Ozempic is approved for type 2 diabetes but is sometimes prescribed off-label for weight loss.

The catch: many insurance plans still don't cover weight loss medications, or they require prior authorization and step therapy (trying other treatments first). Coverage is improving, but slowly.

Cost without insurance: $1,000–$1,400 per month.

2. Novo Nordisk Savings Programs

Novo Nordisk offers savings cards and patient assistance programs:

• Wegovy Savings Card: Eligible patients may pay as little as $0–$25 per month for up to 13 fills.
• Novo Nordisk Patient Assistance Program (PAP): Free medication for qualifying uninsured patients.

Check novocare.com for current offers and eligibility.

3. Oral Wegovy (Coming in 2026)

This is a big deal. The FDA approved an oral (pill) form of semaglutide for weight loss in early 2025, and Novo Nordisk plans to launch the 25 mg oral Wegovy tablet in the US in 2026.

An oral version could be:
- Easier to take (no injections)
- Potentially cheaper to produce
- More widely available

Keep an eye on this. It could change the accessibility picture significantly.

4. Tirzepatide (Mounjaro/Zepbound)

Tirzepatide is the other major GLP-1 weight loss drug. Made by Eli Lilly, it's sold as:

• Mounjaro for type 2 diabetes
• Zepbound for weight loss

Important: Compounded tirzepatide is also banned. The FDA declared the tirzepatide shortage resolved in October/December 2024, with enforcement deadlines in early 2025. So this isn't a workaround — you'll need the brand-name version here too.

However, Eli Lilly has been more aggressive on pricing. They launched LillyDirect, an online pharmacy where Zepbound can cost significantly less through their direct-to-consumer model.

5. Other GLP-1 Medications

Semaglutide and tirzepatide get all the attention, but they're not the only options:

• Liraglutide (Saxenda): An older GLP-1 for weight loss. Less effective than semaglutide but still works. Daily injection.
• Orforglipron: An oral GLP-1 in late-stage clinical trials from Eli Lilly. Could launch in 2026–2027.
• Survodutide, retatrutide, amycretin: Next-generation peptides in clinical trials. Some show even more weight loss than semaglutide.

6. Telehealth Platforms (For Brand-Name Prescriptions)

Many telehealth platforms have pivoted from compounded to brand-name prescriptions:

• Ro (ro.com)
• Found (joinfound.com)
• Calibrate (joincalibrate.com)
• PlushCare (plushcare.com)

These platforms can prescribe FDA-approved medications and help with insurance navigation and prior authorizations. Expect to pay a consultation fee ($50–$200) plus the cost of medication.

---

The Legal Battle

The compounding industry isn't going quietly. Multiple lawsuits have been filed against the FDA:

• Outsourcing Facilities Association vs. FDA: Filed in October 2024 after the tirzepatide shortage was declared resolved. Compounders argued the FDA's decision was premature.
• Additional lawsuits in February 2025: After semaglutide was removed from the shortage list, compounders sued again, calling the decision "reckless and arbitrary."
• Hims & Hers: Facing its own legal challenges, including a securities class action alleging the company misled investors about the sustainability of its compounded semaglutide business.

As of early 2026, this litigation is still working through the courts. Some compounders have received temporary extensions of enforcement deadlines depending on specific court rulings. But the overall direction is clear: the FDA is moving forward with enforcement, and the window for legally compounded semaglutide has closed.

---

What About "Research Peptides"?

If you're seeing websites selling "semaglutide" labeled as "research use only" or "not for human consumption" — stay away. These products:

• Are not made under any pharmaceutical quality standards
• May not contain actual semaglutide (or may contain the wrong amount)
• Have zero safety testing
• Are illegal if marketed for human use regardless of labeling

The FDA is actively targeting these sellers. The risk isn't worth it.

---

The Bottom Line

The compounded semaglutide market was a temporary fix for a real problem: millions of people needed a medication they couldn't afford or access. Compounding pharmacies filled that gap, and for many people, these products worked.

But "temporary" is the key word. The legal basis was always tied to the drug shortage, and that shortage is over.

Here's what to do right now:

1. Don't panic. You have options, even if they require some legwork.
2. Talk to your doctor about transitioning to a brand-name GLP-1 or an alternative treatment.
3. Check your insurance. Coverage for weight loss medications is expanding. You might be surprised.
4. Look into savings programs. Both Novo Nordisk and Eli Lilly offer significant discounts.
5. Watch for oral Wegovy. The pill version launching in 2026 could be a game-changer for accessibility.
6. Avoid black-market products. The risks of counterfeit or unregulated semaglutide are serious and getting worse.

The GLP-1 era isn't over — it's just entering a new phase. Access is going to look different. Prices will likely come down as competition increases and oral versions hit the market. But right now, the transition is messy, and it's hitting the people who could least afford brand-name prices the hardest.

---

Last updated: February 2026

This article is for educational purposes. Talk to a healthcare provider about treatment decisions specific to your situation.